These results demonstrate that PDI-1 treatment inhibits the growth of NSCLC and melanoma tumor cells, likely through a mechanism involving increased recruitment/activation of cytotoxic T cells and reduced recruitment/activation of inhibitory Tregs. The gene discussed is PADI1; the disease is non-small cell lung carcinoma.